| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,713 | 1,715 | 16:08 | |
| 1,708 | 1,716 | 16:04 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 1,760 | 30.000 | |||
| 1,736 | 6.618 | |||
| 1,732 | 5.059 | |||
| 1,730 | 5.059 | |||
| 1,728 | 5.059 | |||
| 1,726 | 5.059 | |||
| 1,725 | 9.999 | |||
| 1,721 | 10.000 | |||
| 1,720 | 15.059 | |||
| 1,719 | 10.504 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/phgn.htm [/URL] | ||||
| 10.000 | 1,712 | |||
| 10.000 | 1,711 | |||
| 5.059 | 1,708 | |||
| 20.000 | 1,707 | |||
| 5.059 | 1,706 | |||
| 5.059 | 1,704 | |||
| 5.059 | 1,702 | |||
| 5.059 | 1,700 | |||
| 13.788 | 1,696 | |||
| 30.000 | 1,670 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 109.083 | 0,939 | 102.416 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 28.01.2026 | 14:43:30 | 1,740 | 7.077 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMING Aktie jetzt für 0€ handeln | |||||
| 21.01. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 274 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
21.01.2026 / 16:13 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 08.01. | Pharming Group N.V. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 08.01. | Pharming Group Sees Higher-than-Expected Revenues In Fiscal 2025 | 6 | RTTNews | ||
| 08.01. | Pharming Group N.V.: Pharming Group reports preliminary 2025 revenues and announces Investor Day | 490 | GlobeNewswire (Europe) | Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full... ► Artikel lesen | |
| 08.12.25 | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | 341 | GlobeNewswire (Europe) | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:33 | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda | EQS Group (DE) | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda
29.01.2026 / 13:27 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| 11:10 | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | sharedeals.de | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| 14:06 | Cycle Group Holdings Limited: Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer | Business Wire | Cycle Group Holdings Limited ("Cycle" or "Parent") today announces that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration... ► Artikel lesen | |
| 14:22 | Fortrea Holdings Inc: Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call | GlobeNewswire (Europe) | DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter... ► Artikel lesen | |
| 08:06 | Scancell Holdings Plc: Interim Results for the six months ended 31 October 2025 | GlobeNewswire (Europe) | OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody and Moditope active immunotherapies to treat cancer, today announces a business... ► Artikel lesen |